The short version of reconstitution fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Hydroxyzine preparations require a doctor's prescription. The drug is available in two formulations, the pamoate and the dihydrochloride or hydrochloride salts. Vistaril, Equipose, Masmoran, and Paxistil are preparations of the pamoate salt, while Atarax, Alamon, Aterax, Durrax, Tran-Q, Orgatrax, Quiess, and Tranquizine are of the hydrochloride salt.
officer and member of the Fire Squad who can also transform into Premiere Deka Red and appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Rui Edogawa is portrayed by Leo Nagatsuma (長妻 怜央, Nagatsuma Reo). Ridomihan Mokumisu (リドミハ星人モクミス, Ridomiha Seijin Mokumisu): A botanical garden curator from Planet Ridomiha who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Mokumisu is voiced by Ayano Kawamura (川村 文乃, Kawamura Ayano), who also portrays her human form. Yoshiwan Raenjo (ヨシワ星人ラエンジョ, Yoshiwa Seijin Raenjo): Tarewarane's wife from Planet Yoshiwa who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Sometime prior to the special, she betrayed Tarewarane to the Space Police to flee his domestic violence. Raenjo is portrayed by Mei Kurokawa (黒川 芽以, Kurokawa Mei). Jiujissonian Rotmen (ジウジッソ星人ロットメン, Jiujisso Seijin Rottomen): Tarewarane's right-hand man from Planet Jiujisso who possesses the ability to assume an alien child form under the alias of Marple (マープル, Māpuru) and appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Following Tarewarane's deletion, Rotmen takes over his boss's plans and takes Rakamu hostage to use Raenjo as his pawn. However, his plans are eventually foiled by the Dekarangers and he is deleted by Ban / Premiere Deka Red. Rotmen is voiced by Jun Fukuyama (福山 潤, Fukuyama Jun).
== Public opinion == In January 2026, Pew Research Center published a poll on American public opinion regarding the Greenland crisis. The results showed that 58% of respondents oppose efforts to take over Greenland, either strongly (45%) or somewhat (13%), while 22% support either strongly (10%) or somewhat (12%), and another 20% were unsure. In Greenland, a poll from January 2025 showed that public opinion was overwhelmingly against American takeover, with 85% reporting opposition to becoming a part of the United States, while 6% supported and 9% were unsure. In a YouGov poll in February 2026 among major Europeans countries, a majority of respondents in all countries polled reported unfavourable views of the United States because of the Greenland crisis. At the same time, a majority in all polled countries reported are sceptical that European countries collectively are able to stand up to the United States, and a plurality of respondents in all countries (except Germany) reported their belief that this US foreign policy is temporary and will only last during the Trump presidency.
Lactic acid bacteria are fastidious organisms that cannot synthesize on their own all of their complex nutritional requirements. For LAB to grow and complete malolactic fermentation, the constitution of the wine medium must provide for their nutritional needs. Like wine yeast, LAB require a carbon source for energy metabolism (usually sugar and malic acid), nitrogen source (such as amino acids and purines) for protein synthesis, and various vitamins (such as niacin, riboflavin, and thiamine) and minerals to assist in the synthesis of enzymes and other cellular components. The source for these nutrients is often found in the grape must itself, though MLF inoculations that run concurrent with alcoholic fermentation risk the yeast outcompeting the bacteria for these nutrients. Towards the end of fermentation, while most of the original grape must resources have been consumed, the lysis of dead yeast cells (the "lees") can be a source for some nutrients, particularly amino acids. Plus, even "dry" wines that have been fermented to dryness still have unfermentable pentose sugars (such as arabinose, ribose and xylose) left behind that can be used by both positive and spoilage bacteria. As with wine yeast, manufacturers of cultured LAB inoculum usually offer specially prepared nutritional additives that be used as a supplement. However, unlike wine yeast, lactic acid bacteria can not use the supplement diammonium phosphate as a nitrogen source.
=== Pusha T's solo career and work relationship with GOOD Music === Before releasing any solo material, Pusha T signed in the autumn of 2010 to GOOD Music, a record label founded by West. That year, he appeared on multiple songs in West's GOOD Fridays series, rapped in the GOOD cypher at the BET Hip Hop Awards, and had two features on West's album My Beautiful Dark Twisted Fantasy. The creative partnership was fruitful; Pusha T became president of GOOD in 2015, and West had production credits on all of his commercially released albums until It's Almost Dry. Pusha T was publicly outspoken about not seeing eye-to-eye with West on politics and career moves multiple times. Among other examples, he expressed disagreement over West's support of Donald Trump and claimed to have different principles on music industry relationships. The relationship had completely deteriorated by late 2022, after West made statements widely condemned as antisemitic. Pusha T said the following in response to West's comments: "It's definitely affected me. It's been disappointing. As a Black man in America, there is no room for bigotry or hate speech. So yeah. It's been very disappointing, let's talk straight." In another interview, he said: "It's beyond [wild stuff] and it's nothing to tap dance around. It's wrong. Period." and "He's not speaking to me now. If you ain't with it, you ain't down. And I ain't with it. I'm not budging on that. I'm not with it." He also clarified that he was no longer the president of GOOD or affiliated with the label in any way.
Sources: en.wikipedia.org
On Valve's official website circa 2010, his function was described as follows: "Kelly is Valve's senior audio producer, responsible for creating sound effects & music." Around March 2011, Kelly Bailey left Valve with colleague Mike Dussault to work on their project Sunspark Labs LLC, launched in December 2010, developing iOS applications, their first being "Morfo", released in June 2011. The news caused some concern and displeasure from the Steam community due to the lack of any public farewell or notification regarding Bailey's departure. However, at a press conference in February 2014, Mike Morasky (the current composer at Valve), stated that Kelly Bailey was working with Valve again. On 24 September 2015, a collection of new music composed by Bailey was released as a custom music kit in Counter-Strike: Global Offensive titled Hazardous Environments. The music kit's description states that it was "inspired by the darker side of the Half-Life universe". On 18 March 2016, Forbes wrote that Bailey is no longer with Valve but that he has created his own video game company, IndiMo Labs, and that he had been spending sixteen hours a day for the previous seven months as the sole developer behind Vanishing Realms: Rite of Steel, a virtual reality video game with RPG elements for the HTC Vive. The game released as an early access title on Steam on 5 April 2016, the same day the HTC Vive was launched.
They can be synthesized/released and broken down again in specific reactions by enzymes or ion channels. Some (such as Ca2+) can be stored in special organelles and quickly released when needed. Their production/release and destruction can be localized, enabling the cell to limit space and time of signal activity.
In fantasy fiction, a lich () is a type of undead creature with magical powers. Various works of fantasy fiction, such as Clark Ashton Smith's "The Empire of the Necromancers" (1932), had used lich as a general term for any corpse, animate or inanimate, before the term's specific use in fantasy role-playing games. The more recent use of the term lich for a specific type of undead creature originates from the 1976 Dungeons & Dragons role-playing game booklet Greyhawk, written by Gary Gygax and Rob Kuntz. Often such a creature is the result of a willful transformation, as a powerful wizard skilled in necromancy who seeks eternal life uses rare substances in a magical ritual to become undead. Unlike zombies, which are often depicted as mindless, liches are sapient revenants, retaining their previous intelligence and magical abilities. Liches are often depicted as holding power over lesser mindless undead soldiers and servants. A lich's most commonly depicted distinguishing feature, compared to other undead in fantasy fiction, is the method by which it achieves immortality: liches surrender their souls to create "soul-artifacts" (often called a "soul gem" or "phylactery" in other fantasy works), which serve as the source of their magic and immortality. Many liches take precautions to hide and/or protect one or more of these soul-artifacts, which anchor parts of their souls to the material world.
== Etymology == The name pyrite is derived from the Greek πυρίτης λίθος (pyritēs lithos), 'stone or mineral which strikes fire', in turn from πῦρ (pŷr), 'fire'. In ancient Roman times, this name was applied to several types of stone that would create sparks when struck against steel; Pliny the Elder described one of them as being brassy, almost certainly a reference to what is now called pyrite. By Georgius Agricola's time, c. 1550, the term had become a generic term for all of the sulfide minerals.
Sources: en.wikipedia.org
Representative James Talarico legislative website Talarico for Texas U.S. Senate campaign website Financial information (federal office) at the Federal Election Commission Profile at Vote Smart Appearances on C-SPAN
=== Starting material === PMCA was originally based on the normal prion protein (PrPC) from healthy brain tissue, which is expensive. The advent of recombinant proteins have lower the cost somewhat, but the steps required to obtain the pure protein are laborious. In 2011, it was found that simply putting a prion protein transgene into a cell line and then lysing the cell without purification is enough. This is expected to make PMCA much cheaper. The cell line does not need to be of a neuronal origin. PMCA is most easily performed with catalysts which are abundant even in healthy cells: a polyanion (single-stranded RNA or sulfated glycans) and a phospholipid. A cell lysate would provide both of these catalysts and most clumps of PrPSc contain catalyst polyanion molecules anyways. Synthetic versions of these catalysts such as poly(A) RNA and 1-palmitoyl-2-oleoylphosphatidylglycerol (POPG) also work for propagating PrPSc. Additional required materials include buffer salts and detergent.
== Personal life == Prior to moving to Los Angeles, Johnny was employed as a Manager at Microsoft in Chicago, Illinois. He is an avid golfer and won The Golf Channel's 2006 The Big-Break All Star Challenge Scrubs competition, beating out Robert Maschio ("The Todd") in the final match. While attending law school at the University of Iowa, he worked as a law clerk at the U.S. Attorney's Office. He practiced law in Chicago, Illinois, at the law firms of Katten Muchin Rosenman and Dentons before becoming a Founding Member (and VP of Business Development and Strategic Partnerships) of Acorn Finance.
== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.